New MammaTyper® research presented:

Last week the 8th Hellenic Congress of Medical Oncology took place in Thessaloniki.

Dr Kolesta presented our latest MammaTyper® research abstract:

Comparative evaluation of immunohistochemcial and MammaTyper® subtyping in breast cancer: Clinical and therapeutic implications

Led by support from our distributors P. Zafiropoulos S.A.

Conclusions:

“Molecular classification according to MammaTyper® demonstrated a high degree of agreement with IHC-based subtyping but also instances of reclassification with potential clinical significance.”

A molecular approach to subtyping and classification in HER2-low expression categories can serve as a complement to IHC. Particularly in borderline or uncertain cases.

Studies also support the greater reproducibility and objectivity of MammaTyper® in the assessment of Ki-67 and in distinguishing HER2-low/ultralow breast carcinomas.

Find out more about MammaTyper®, including research supporting its use in breast cancer diagnostics: https://lnkd.in/d2YPtvBD